Fig. 2From: Integrating cfDNA liquid biopsy and organoid-based drug screening reveals PI3K signaling as a promising therapeutic target in colorectal cancerthe features of variants detected by cfDNA liquid biopsy. A barplot showing the proportion of each type of mutation detected by liquid biopsy. B Mutation signature of all variants detected in liquid biopsy. C Barplot showing the number of mutations detected in each sample. D Oncoprint plot showing all variants detected in each gene and sampleBack to article page